EULAR Quality of Care Study Groups 

EULAR study groups are established networks in their respective fields and play an active part in the research and treatment of rheumatic and musculoskeletal diseases. Below is an overview of the EULAR Quality of Care Study Groups. Each study group overview contains a description and links to further information. Scroll down for further information.

Focus groups in the area of musculoskeletal medicine may apply for EULAR endorsement and also for support through the EULAR Quality of Care Committee.

How to apply to a EULAR Study Group:

 Please see more information here

Reproductive Health and Family Planning (ReHFaP)

There is an increasing focus on topics related to reproductive health (ReH) and family planning (FaP) in patients with autoimmune, rheumatic and musculoskeletal diseases (RMD). Both patients, physicians and the broader multidisciplinary team recognize the challenges in communication about reproductive issues.
Read more
Biennial report 2024

 

Lung involvement in Rheumatic Musculoskeletal diseases

The EULAR Study Group on lung involvement including interstitial lung diseases (ILDs) in rheumatic and musculoskeletal diseases (RMDs) aims to bring together an international group of experts with a special interest in lung involvement and ILDs. The study group partly evolved from the EULAR task force “ERS/EULAR Clinical practice guideline on Connective tissue diseases with ILD”.
Read more
Biennial report 2024

 

EULAR Implementation Study Group

This is a study group that started in a EULAR Task Force on implementation. This task force proposed several standardised operating procedures for implementing recommendations (available at the EULAR website). In addition, the Task Force has published an article in Ann Rheum Dis entitled “Implementation of recommendations in rheumatic and musculoskeletal diseases: Considerations for development and uptake”.
Read more
Biennial report 2024

 

EULAR Study Group on Systemic Autoinflammatory Diseases

The Study Group on Systemic Autoinflammatory Disorders will be open to the contribution of any new Applicant among clinicians, researchers, allied health professionals and patients from European and non-European Countries. The study group shall meet at least annually during the EULAR Congress. Ordinary communication between members will be maintained throughout the year by e-mail.
Read more
Biennial report 2024

 

EULAR Systemic Lupus Erythematosus (SLE) Study Group

This is a study group that evolved from the EULAR Task Force on SLE. It has published recommendations on the diagnosis and management of SLE, neuropsychiatric lupus and lupus nephritis in the Ann Rheum Dis (available at the EULAR website). The task force has also published recommendations on points to consider when conducting lupus clinical trials.
Read more
Biennial report 2024

 

EULAR OA Trial Data Bank Study Group

Based on small to moderate effectiveness of the wide range of symptomatic treatments in OA, and the heterogeneity of OA patients, treatment guidelines for OA have stressed the need for research on clinical predictors of response to different treatments. EULAR endorses this inititative and will help increase visibility for all data-deliverers and all individuals interested in joining this study group.
Read more
Biennial report 2024

 

EULAR Lupus Nephritis Trial Network Study Group

The mission of the Lupus Nephritis Trial Network (LNTN) has been designed to improve outcomes for patients with lupus nephritis through: (1) the conduct of clinical trials designed to prevent chronic kidney disease and end-stage kidney failure, and (2) the development of clinical trial methodologies that improve and simplify the assessment of therapeutic agents.
Read more
Biennial report 2024

 

EULAR Myositis Study Group - MyoNet

This study group is an open forum designed to enhance knowledge on myositis and to facilitate research and clinical trials in myositis.
Read more
Biennial report 2024

 

EULAR Cardiovascular involvement in Inflammatory arthritis (CVIIA) Study Group

The study group is open to anyone interested in the diagnosis, treatment and prognosis of patients with CV and RA and/or SpA.                                                                         
Read more
Biennial report 2024

 

EULAR Therapeutic Drug Monitoring Study Group

Therapeutic drug monitoring (TDM) of biologics is a potentially important development in the management of patients with a variety of rheumatic conditions. It refers explicitly to the measurement of circulating drug concentrations (drug levels), and anti-drug antibodies, in patients receiving biologic drugs. The purpose of this EULAR Study Group is to debate different questions on this subject.
Read more
Biennial report 2024

 

EULAR Hemochromatosis arthropathy Study Group

The aim of this study group is to discuss many of the aspects of this arthropathy that we have all individually recognized, support patient associations by providing talks to patient groups (e.g Birmingham, Belfast)
Read more
Biennial report 2022

 

EULAR Antiphospholipid Syndrome (APS) Study Group

The aim of this study group is to develop a network -with emphasis on young participants- involving fellows, PhD students, rheumatologists, clinical immunologists, basic researchers, patients, and health professionals with interest in APS.
​Read more​
​Biennial report 2023​​

 

EULAR Study Group on Anatomy for the Image

Read more
Biennial report 2021

 

EULAR Diffuse Idiopathic Skeletal Hyperostosis Study Group

The DISH Study Group aims to investigate the clinical presentation and diagnostic procedures patients suffering from or being suspicious for the diagnosis of DISH. Since the early clinical symptoms of this disease are unclear, the relations to new bone formation, axial and peripheral joint pain and the occurrence of a metabolic syndrome need further clarification. Furthermore, the best suitable diagnostic criteria still need to be identified from the many proposals that exist in literature.
Read more
Biennial report 2024

EULAR STUDY Group on Polymyalgia Rheumatica and Giant Cell Arteritis

Read more